WO2012096329A1 - 一塩基多型の検出方法 - Google Patents
一塩基多型の検出方法 Download PDFInfo
- Publication number
- WO2012096329A1 WO2012096329A1 PCT/JP2012/050430 JP2012050430W WO2012096329A1 WO 2012096329 A1 WO2012096329 A1 WO 2012096329A1 JP 2012050430 W JP2012050430 W JP 2012050430W WO 2012096329 A1 WO2012096329 A1 WO 2012096329A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- single nucleotide
- group
- pcr
- guanidine
- mutant
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/137—Chromatographic separation
Definitions
- the present invention relates to a rapid and simple method for detecting a single nucleotide polymorphism.
- a primer is set at the common sequence site, and polymorphism is present inside the PCR amplification product, that is, within the PCR amplification product.
- the amplified PCR product is cleaved with a restriction enzyme, and the presence or absence of a polymorphism is determined by the length of the fragment.
- a restriction enzyme since a restriction enzyme is used, there are problems such as an increase in analysis cost and a long analysis time.
- the difference in chain length is detected by electrophoresis, there are problems such as complicated operations and a long analysis time.
- Non-Patent Document 1 discloses a method for separating nucleic acid-related compounds by high performance liquid chromatography. However, even the method disclosed in Non-Patent Document 1 has a problem that it is difficult to sufficiently separate nucleic acids having different chain length differences such as single nucleotide polymorphisms.
- An object of the present invention is to provide a rapid and simple method for detecting a single nucleotide polymorphism.
- the present invention is a single nucleotide polymorphism detection method in which wild-type and mutant products amplified by the AS-PCR method are analyzed using ion-exchange chromatography.
- the present invention is described in detail below.
- the present inventors have found that single nucleotide polymorphisms can be detected quickly and easily by analyzing the wild-type and mutant products amplified by the AS-PCR method using ion exchange chromatography.
- the invention has been completed.
- the AS-PCR (Allele Specific-PCR) method is a method for detecting a gene polymorphism (particularly a single nucleotide polymorphism) using a sequence-specific amplification reaction. Specifically, PCR is performed so that the nucleotide sequence of the single nucleotide polymorphism to be detected is the 3 'end of the primer. When the sequence of the target nucleic acid and the primer are completely complementary, an extension reaction occurs by DNA polymerase. On the other hand, when the sequence of the target nucleic acid and the primer are incompletely complementary, the extension reaction of DNA polymerase is inhibited.
- this is a method for determining a single nucleotide polymorphism based on the result of an amplification reaction using two kinds of primers having a single nucleotide polymorphism wild-type or mutant nucleotide sequence at the 3 'end.
- AS-PCR method the method disclosed in “Nature, 324, p.163-166, 1986” can be used.
- ion exchange chromatography is used. It is preferable that the eluent used for ion exchange chromatography contains a guanidine salt derived from guanidine represented by the following formula (1).
- guanidine salts include guanidine hydrochloride, guanidine sulfate, guanidine nitrate, guanidine carbonate, guanidine phosphate, guanidine thiocyanate, guanidine sulfamate, aminoguanidine hydrochloride, aminoguanidine bicarbonate, and the like. It is done. Of these, guanidine hydrochloride and guanidine sulfate are preferably used.
- the concentration of the guanidine salt in the eluent at the time of analysis may be appropriately adjusted according to the substance to be detected, but is desirably 2000 mmol / L or less. Specifically, a method of performing gradient elution with a guanidine salt concentration in the range of 0 to 2000 mmol / L can be mentioned. Therefore, the concentration of guanidine salt at the start of analysis need not be 0 mmol / L, and the salt concentration of guanidine salt at the end of analysis need not be 2000 mmol / L.
- the gradient elution method may be a low pressure gradient method or a high pressure gradient method, but a method of eluting while performing precise concentration adjustment by the high pressure gradient method is preferred.
- the guanidine salt may be added to the eluent alone or in combination with other salts.
- the salt that can be used in combination with the guanidine salt include, for example, a salt composed of a halide such as sodium chloride, potassium chloride, sodium bromide, potassium bromide and an alkali metal, calcium chloride, calcium bromide, magnesium chloride.
- salts of halides such as magnesium bromide and alkaline earth metals, and inorganic acid salts such as sodium perchlorate, potassium perchlorate, sodium sulfate, potassium sulfate, ammonium sulfate, sodium nitrate, potassium nitrate, etc.
- organic acid salts such as sodium acetate, potassium acetate, sodium succinate, potassium succinate and the like may be used.
- buffers and organic solvents can be used. Specifically, for example, Tris hydrochloric acid buffer, TE buffer composed of Tris and EDTA, Tris, acetic acid and EDTA are used. And a TBA buffer solution consisting of Tris, boric acid and EDTA.
- the pH of the eluent is not particularly limited as long as the nucleic acid chain can be separated by anion exchange.
- those having a cationic group introduced on at least the surface of the base particle are preferable, and those having a strong cationic group and a weak anionic group on at least the surface of the base particle. Is more preferable.
- the “strong cationic group” means a cationic group that dissociates in a wide range of pH from 1 to 14. That is, the strong cationic group can be kept dissociated (cationized) without being affected by the pH of the aqueous solution.
- a quaternary ammonium group is mentioned as a strong cationic group.
- Specific examples include trialkylammonium groups such as a trimethylammonium group, a triethylammonium group, and a dimethylethylammonium group.
- examples of counter ions of strong cationic groups include halide ions such as chloride ions, bromide ions, and iodide ions.
- the amount of the strong cationic group is not particularly limited, but the preferable lower limit per dry weight of the filler is 1 ⁇ eq / g, and the preferable upper limit is 500 ⁇ eq / g.
- the amount of the strong cationic group is less than 1 ⁇ eq / g, the holding power of the filler is weakened, and the separation performance may be deteriorated.
- the amount of the strong cationic group exceeds 500 ⁇ eq / g, the retention of the filler becomes too strong, the detection target substance cannot be easily eluted, and problems such as a long analysis time may occur.
- the “weak anionic group” means an anionic group having a pKa of 3 or more. That is, the weak anionic group is affected by the pH of the aqueous solution, and the dissociation state changes. When the pH is higher than 3, the protons of the carboxy group are dissociated and the proportion of negative charges increases. On the other hand, when the pH is lower than 3, the proportion of the non-dissociated state in which the carboxy group protons are bonded increases.
- the weak anionic group include a carboxy group and a phosphate group. Of these, a carboxy group is preferable.
- Examples of a method for introducing a carboxy group into at least the surface of the base particle include, for example, a method of copolymerizing a monomer having a carboxy group, a method of hydrolyzing an ester portion in the monomer, and a carboxy group by treatment with ozone water.
- a method of forming a carboxy group by ozone gas, a method of forming a carboxy group by plasma treatment, a method of reacting a silane coupling agent having a carboxy group, an epoxy group by copolymerizing a monomer having an epoxy group A known method such as a method of forming a carboxy group by ring opening of can be used.
- the base particle has a hydrophobic structure portion, particularly a carbon-carbon double bond, it is preferable to use a method of forming a carboxy group by treatment with ozone water.
- Ozone is highly reactive with a double bond, and ozone that has reacted with the double bond forms an ozonide that is an intermediate, and then a carboxy group or the like is formed.
- Ozone water means that ozone gas is dissolved in water.
- the particle surface can be easily oxidized simply by dispersing the particles in ozone water.
- hydrophilic groups such as a carboxy group, a hydroxyl group, an aldehyde group, and a keto group are formed.
- Ozone has a strong oxidizing effect, but by treating with ozone water, the particle surface can be oxidized more uniformly than by treating with ozone gas, and carboxy groups are formed more uniformly. preferable.
- concentration of the dissolved ozone in ozone water is not specifically limited, A preferable minimum is 20 ppm.
- concentration of dissolved ozone is less than 20 ppm, it takes a long time to form a carboxy group, or the formation of a carboxy group becomes insufficient, and the nonspecific adsorption of the detection target substance is sufficiently suppressed. I cannot do it.
- a more preferable lower limit of the concentration of dissolved ozone is 50 ppm.
- ozone water is a method in which raw water and ozone gas are brought into contact with each other through an ozone gas permeable film that allows only gas to pass and blocks liquid from passing through. Can be prepared.
- the carboxy group introduced on the surface of the substrate particle is almost dissociated, and it is considered that a weak cation exchange interaction occurs with a few cations in the nucleobase.
- hydrophilic groups such as hydroxyl groups, aldehyde groups and keto groups are formed in addition to carboxy groups, and the presence of these hydrophilic groups acts between the surface of the filler and the nucleic acid. It is thought that the hydrophobic interaction is weakened.
- the amount of the weak anionic group introduced into at least the surface of the base particle is not particularly limited as long as it is equal to or less than the strong cationic group amount.
- the base particles for example, synthetic polymer fine particles obtained using a polymerizable monomer, inorganic fine particles such as silica-based particles can be used, and hydrophobic crosslinked polymer particles made of organic synthetic polymers. And a layer made of a hydrophilic polymer having an ion exchange group copolymerized on the surface of the hydrophobic crosslinked polymer particles.
- Hydrophobic crosslinked polymer is a hydrophobic crosslinked polymer obtained by homopolymerizing one kind of hydrophobic crosslinkable monomer, and obtained by copolymerizing two or more kinds of hydrophobic crosslinkable monomers. Any of a crosslinked polymer and a hydrophobic crosslinked polymer obtained by copolymerizing at least one hydrophobic crosslinking monomer and at least one hydrophobic non-crosslinking monomer may be used.
- the hydrophobic crosslinkable monomer is not particularly limited as long as it has two or more vinyl groups in one monomer molecule.
- ethylene glycol di (meth) acrylate, polyethylene glycol di (meth) acrylate , Propylene glycol di (meth) acrylate, polypropylene glycol di (meth) acrylate and other di (meth) acrylates tetramethylol methane tri (meth) acrylate, trimethylol propane tri (meth) acrylate, tetramethylol methane tetra
- Examples include tri (meth) acrylic acid esters such as (meth) acrylate or tetra (meth) acrylic acid esters, and aromatic compounds such as divinylbenzene, divinyltoluene, divinylxylene, and divinylnaphthalene.
- (meth) acryl means “acryl or methacryl”
- (meth) acrylate” means “acrylate or
- the hydrophobic non-crosslinkable monomer is not particularly limited as long as it is a non-crosslinkable polymerizable organic monomer having hydrophobic properties.
- methyl (meth) acrylate, ethyl (meth) acrylate, propyl examples thereof include (meth) acrylates such as (meth) acrylate, isopropyl (meth) acrylate, butyl (meth) acrylate and t-butyl (meth) acrylate, and styrene monomers such as styrene and methylstyrene.
- the hydrophobic cross-linked polymer consists of a copolymer of a hydrophobic cross-linkable monomer and a hydrophobic non-cross-linkable monomer
- the inclusion of segments derived from the hydrophobic cross-linkable monomer in the hydrophobic cross-linked polymer is 10% by weight, and the more preferable lower limit is 20% by weight.
- the hydrophilic polymer having an ion exchange group is composed of a hydrophilic monomer having an ion exchange group, and includes a segment derived from a hydrophilic monomer having one or more ion exchange groups.
- Good That is, as a method for producing a hydrophilic polymer having an ion exchange group, a method in which a hydrophilic monomer having an ion exchange group is polymerized alone, a hydrophilic monomer having an ion exchange group and an ion exchange group are used. And a method of copolymerizing with a hydrophilic monomer not to be used.
- the hydrophilic monomer having an ion exchange group preferably has a strong cationic group, and more preferably has a quaternary ammonium group.
- Examples include acrylamidoethyltrimethylammonium chloride, acrylamidoethyltriethylammonium chloride, and acrylamidoethyldimethylethylammonium chloride.
- the average particle diameter of the filler is not particularly limited, but a preferable lower limit is 0.1 ⁇ m and a preferable upper limit is 20 ⁇ m.
- a preferable lower limit is 0.1 ⁇ m and a preferable upper limit is 20 ⁇ m.
- the average particle size of the packing material is less than 0.1 ⁇ m, the internal pressure of the column becomes high, which may cause poor separation. If the average particle size of the packing material exceeds 20 ⁇ m, the dead volume in the column becomes too large and may cause poor separation.
- an average particle diameter shows a volume average particle diameter, and can be measured using a particle size distribution measuring apparatus (made by AccuSizer780 / Particle Sizing Systems).
- the size of the product amplified by the AS-PCR method is preferably 200 bp or less. If the size of the product amplified by the AS-PCR method exceeds 200 bp, the PCR amplification time or the analysis time in ion exchange chromatography may become long, or sufficient separation performance may not be obtained.
- the size of the product amplified by the AS-PCR method is more preferably 100 bp or less.
- the difference in product size (chain length difference) between the wild type and the mutant type amplified by the AS-PCR method is preferably 10 bp or less. Even if the AS primer is designed so that the difference in size between the amplified wild-type product and the mutant product exceeds 10 bp, a desired amplification product may not be obtained in a non-specific amplification reaction or the like.
- a rapid and simple method for detecting a single nucleotide polymorphism can be provided.
- Example 1 it is the chromatogram obtained by isolate
- FIG. 1 it is the chromatogram obtained by isolate
- FIG. 1 it is a chromatogram obtained by separating and detecting wild type 271 bp and mutant type 274 bp in the UGT1A1 * 6 region using an anion exchange column 1.
- Reference Example 1 it is a chromatogram obtained by separating and detecting wild type 271 bp and mutant type 274 bp in the UGT1A1 * 6 region using an anion exchange column 2.
- Reference Example 2 it is a chromatogram obtained by separating and detecting wild type 76 bp and mutant type 79 bp in the UGT1A1 * 6 region using the anion exchange column 1.
- ozone water is 400 hollow-tube ozone gas permeable membranes having an inner diameter of 0.5 mm, a thickness of 0.04 mm, and a length of 350 cm made of perfluoroalkoxy resin in a jacket having a cylindrical shape with an inner diameter of 15 cm and a length of 20 cm. It was prepared using an ozone water production system (manufactured by Sekisui Chemical Co., Ltd.) containing the accommodated ozone dissolution module. The obtained filler for ion exchange chromatography was measured using a particle size distribution analyzer (Particulate Sizing Systems, “Accurizer 780”), and the average particle size was 10 ⁇ m. The following column (anion exchange column 1) was prepared using the obtained packing material for ion exchange chromatography. Column size: inner diameter 4.6 mm x 20 mm Ion exchange group: quaternary ammonium group
- Example 1 In Example 1, separation detection of wild type 76 bp and mutant type 79 bp of the UGT1A1 * 6 region was performed.
- reaction C1000 Bio-Rad Laboratories
- the temperature cycle is as follows.
- the template was thermally denatured at 94 ° C. for 30 seconds, 40 cycles of 94 ° C. for 15 seconds, 62 ° C. for 15 seconds, and 68 ° C. for 30 seconds were performed, and finally the temperature was kept at 68 ° C. for 5 minutes. Samples were stored at 4 ° C. until use.
- Reference Example 1 separation detection of wild type 271 bp and mutant type 274 bp in the UGT1A1 * 6 region was performed.
- reaction C1000 Bio-Rad Laboratories
- the temperature cycle is as follows.
- the template was thermally denatured at 94 ° C. for 30 seconds, 40 cycles of 94 ° C. for 15 seconds, 62 ° C. for 15 seconds, and 68 ° C. for 30 seconds were performed, and finally the temperature was kept at 68 ° C. for 5 minutes. Samples were stored at 4 ° C. until use.
- Comparative Example 1 In Comparative Example 1, an attempt was made to separate and detect wild type 76 bp and mutant type 96 bp of the UGT1A1 * 6 region.
- reaction C1000 Bio-Rad Laboratories
- the temperature cycle is as follows.
- the template was thermally denatured at 94 ° C. for 30 seconds, 40 cycles of 94 ° C. for 15 seconds, 62 ° C. for 15 seconds, and 68 ° C. for 30 seconds were performed, and finally the temperature was kept at 68 ° C. for 5 minutes. Samples were stored at 4 ° C. until use.
- Reference Example 2 separation detection of wild type 76 bp and mutant type 79 bp in the UGT1A1 * 6 region was performed.
- HPLC analysis was performed using anion exchange column 2 in the same manner as in Example 1 except that sodium chloride was used instead of guanidine hydrochloride as the salt added to eluent B.
- Example 1 chromatograms obtained by separating and detecting wild type 76 bp and mutant type 79 bp of UGT1A1 * 6 region are shown in FIG. 1 (when anion exchange column 1 is used) and FIG. When used). From the results shown in FIGS. 1 and 2, both columns were able to successfully separate and detect wild-type 76 bp and mutant-type 79 bp of UGT1A1 * 6 region amplified by AS-PCR. In particular, when the anion exchange column 1 was used, almost complete separation and detection could be achieved in a short time.
- FIG. 3 chromatograms obtained by separating and detecting wild type 271 bp and mutant type 274 bp in the UGT1A1 * 6 region are shown in FIG. 3 (when anion exchange column 1 is used) and FIG. When used). From the results of FIGS. 3 and 4, in contrast to Example 1, it was not possible to separate the wild type 271 bp and the mutant type 274 bp of the UGT1A1 * 6 region amplified by AS-PCR. This is considered to be because the difference in chain length between the wild type and the mutant type was small with respect to the size of the AS-PCR amplification product.
- FIG. 5 shows a chromatogram obtained by separating and detecting wild type 76 bp and mutant type 79 bp in the UGT1A1 * 6 region using the anion exchange column 2 in Reference Example 2.
- sodium chloride was added to eluent B instead of guanidine hydrochloride, wild type 76 bp and mutant type 79 bp could not be separated.
- a rapid and simple method for detecting a single nucleotide polymorphism can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
一塩基多型を解析する方法として、RFLP法(Restriction Fragmet Length Polymorphism)が知られている。RFLP法は、PCR(Polymerase Chain Reaction)増幅産物中の遺伝子変異部位を認識する制限酵素が存在する場合、共通配列部位にプライマーを設定し、その内側、すなわち、PCR増幅産物内に多型性をもたせて増幅し、得られたPCR産物を制限酵素で切断し、その断片の長さにより、多型の有無を判定する方法である。しかしながら、制限酵素を用いるため、分析コストが上がったり、解析全体の時間が長くなったりする等の課題がある。また、電気泳動により鎖長差を検出するため、作業が煩雑になったり、解析全体の時間が長くなったりする等の課題もある。
以下に本発明を詳述する。
イオン交換クロマトグラフィーに用いる溶離液は、下記式(1)で示されるグアニジンから誘導されるグアニジン塩を含有することが好ましい。
具体的には、グアニジン塩の濃度を0~2000mmol/Lの範囲でグラジエント溶出させる方法を挙げることができる。従って、分析開始時のグアニジン塩の濃度は0mmol/Lである必要はなく、また、分析終了時のグアニジン塩の塩濃度も2000mmol/Lである必要はない。
グラジエント溶出の方法は、低圧グラジエント法であっても高圧グラジエント法であってもよいが、高圧グラジエント法による精密な濃度調整を行いながら溶出させる方法が好ましい。
また、強カチオン性基のカウンターイオンとしては、例えば、塩化物イオン、臭化物イオン、ヨウ化物イオン等のハロゲン化物イオンが挙げられる。
上記弱アニオン性基としては、例えば、カルボキシ基、リン酸基等が挙げられる。なかでも、カルボキシ基であることが好ましい。
オゾンは二重結合との反応性が高く、二重結合と反応したオゾンは、中間体であるオゾナイドを形成し、その後、カルボキシ基等が形成される。
オゾン水を用いることにより、オゾン水中に粒子を分散させるだけで粒子表面を簡便に酸化させることができる。その結果、基材粒子における疎水性の構造部分が酸化され、カルボキシ基、水酸基、アルデヒド基、ケト基等の親水性基が形成されると考えられる。
オゾンには強力な酸化作用があるが、オゾン水を用いて処理することにより、オゾンガスを用いて処理するよりも粒子表面を均一に酸化させることができ、より均一にカルボキシ基が形成されるので好ましい。
また、オゾン水によって処理することで、カルボキシ基の他、水酸基、アルデヒド基、ケト基等の親水性基が形成され、これらの親水性基の存在によって充填剤の表面と核酸との間に働く疎水性相互作用が弱まると考えられる。
従って、少なくとも表面に強カチオン性基と弱アニオン性基とを有する充填剤を用いた場合、主たる相互作用である充填剤表面と核酸との間に働くアニオン交換相互作用に加え、上述したように、弱いカチオン交換相互作用が働いたり、疎水性相互作用が弱まったりすることによって分離性能が向上するものと考えられる。
なお、本明細書において、「(メタ)アクリル」とは、「アクリル又はメタクリル」を意味し、「(メタ)アクリレート」とは、「アクリレート又はメタクリレート」を意味する。
なお、本明細書において平均粒子径は体積平均粒子径を示し、粒度分布測定装置(AccuSizer780/Particle Sizing Systems社製)を用いて測定することができる。
(アニオン交換カラム1)
攪拌機付き反応器中にて、3重量%ポリビニルアルコール(日本合成化学社製)水溶液2000mLに、テトラエチレングリコールジメタクリレート(新中村化学工業社製)300g、トリエチレングリコールジメタクリレート(新中村化学工業社製)100g、及び、過酸化ベンゾイル(キシダ化学社製)1.0gの混合物を添加した。攪拌しながら加熱し、窒素雰囲気下にて80℃で1時間重合した。次に、強カチオン性のイオン交換基(4級アンモニウム基)を有する単量体として、メタクリル酸エチルトリメチルアンモニウムクロリド(和光純薬工業社製)100gをイオン交換水に溶解し、得られた溶液を上記反応器中に更に添加した。次いで、攪拌しながら窒素雰囲気下にて80℃で2時間重合し、重合体組成物を得た。得られた重合体組成物を水及びアセトンで洗浄することにより、基材粒子の表面に4級アンモニウム基を有する親水性の被覆重合体粒子を得た。
得られた被覆重合体粒子10gを溶存オゾン濃度100ppmのオゾン水300mLに浸漬し、30分間攪拌した。攪拌終了後、遠心分離機(日立製作所社製、「Himac CR20G」)を用いて遠心分離し、上澄みを除去した。この操作を2回繰り返し、被覆重合体粒子にオゾン水処理を施し、4級アンモニウム基とカルボキシ基が共存するイオン交換クロマトグラフィー用充填剤を得た。
なお、オゾン水は、内径15cm×長さ20cmの円柱形を有する外套内に、パーフルオロアルコキシ樹脂からなる内径0.5mm×厚さ0.04mm×長さ350cmの中空管状のオゾンガス透過膜400本収容されたオゾン溶解モジュールを含むオゾン水製造システム(積水化学工業社製)を用いて調製した。
得られたイオン交換クロマトグラフィー用充填剤について、粒度分布計(Particle Sizing Systems社製、「Accusizer780」)を用いて測定したところ、平均粒子径は10μmであった。
得られたイオン交換クロマトグラフィー用充填剤を用いて以下のカラム(アニオン交換カラム1)を準備した。
カラムサイズ:内径4.6mm×20mm
イオン交換基:4級アンモニウム基
市販されているカラムとして、以下のカラムを準備した。
品名:TSK-gel DNA-STAT(東ソー社製)
カラムサイズ:内径4.6mm×長さ100mm
イオン交換基:4級アンモニウム基
実施例1では、UGT1A1*6領域の野生型76bpと変異型79bpとの分離検出を行った。
以下に示すAS-PCR条件によって野生型と変異型の増幅産物を得た。
(1)試薬
AccuPrime Taq DNA Polymerase High Fidelity(Invitorgen社製、Lot.760816)
10×AccuPrime PCR Buffer I
AccuPrime Taq DNA Polymerase High Fidelity(5U/μL)
UGT1A1*6 primer(Operon Biotechnologies社製)
Forward(野生型)(10pmol/μL):5’-(cgcctcgttgtacatcagagcgg)-3’(配列番号1)
Forward(変異型)(10pmol/μL):5’-(ctgacgcctcgttgtacatcagagcga)-3”(配列番号2)
Reverse(10pmol/μL):5’-(cacatcctccctttggaatggca)-3”(配列番号3)
Nuclease-free Water(not DEPC-treated)(Ambion社製、Lot.0803015)
UGT1A1遺伝子 野生型配列挿入プラスミド(1×106コピー/μL)
UGT1A1遺伝子 変異型配列挿入プラスミド(1×106コピー/μL)
5μLの10×AccuPrime PCR Buffer I、1μLのForward primer、1μLのReverse priemrに総量が49μLとなるようNuclease-free Waterで調整した溶液に、1μLのUGT1A1遺伝子配列挿入プラスミドを添加し反応溶液とした。
C1000(バイオ・ラッド ラボラトリーズ社製)を用いて、PCR反応を行った。温度サイクルは以下に示す通りである。
94℃、30秒でテンプレートを熱変性させ、94℃を15秒、62℃を15秒、68℃を30秒の増幅サイクルを40サイクル行い、最後に68℃、5分で保温した。サンプルは使用するまで4℃で保存した。
準備したアニオン交換カラムを用いて、以下の条件でAS-PCR増幅産物を分離検出した。
システム:LC-20Aシリーズ(島津製作所社製)
溶離液:溶離液A 25mmol/Lトリス塩酸緩衝液(pH7.5)
溶離液B 25mmol/Lトリス塩酸緩衝液(pH7.5)+1mol/Lグアニジン塩酸塩
分析時間:アニオン交換カラム1を用いたときの分析時間は10分
アニオン交換カラム2を用いたときの分析時間は20分
溶出法:以下に示すグラジエント条件により、溶離液Bの混合比率を直線的に増加させた。
アニオン交換カラム1を用いたときの条件
0分(溶離液B40%)→10分(溶離液B50%)
アニオン交換カラム2を用いたときの条件
0分(溶離液B70%)→20分(溶離液B90%)
検体:UGT1A1*6領域の野生型76bp
UGT1A1*6領域の変異型79bp
流速:0.5mL/min(アニオン交換カラム1を用いたとき)
1.0mL/min(アニオン交換カラム2を用いたとき)
検出波長:260nm
試料注入量:10μL
参考例1では、UGT1A1*6領域の野生型271bpと変異型274bpとの分離検出を行った。
以下に示すAS-PCR条件によって野生型と変異型の増幅産物を得た。
AccuPrime Taq DNA Polymerase High Fidelity(Invitorgen社製、Lot.760816)
10×AccuPrime PCR Buffer I
AccuPrime Taq DNA Polymerase High Fidelity(5U/μL)
UGT1A1*6 primer(Operon Biotechnologies社製)
Forward(野生型)(10pmol/μL):5’-(cgcctcgttgtacatcagagcgg)-3’(配列番号1)
Forward(変異型)(10pmol/μL):5’-(ctgacgcctcgttgtacatcagagcga)-3”(配列番号2)
Reverse(10pmol/μL):5’-(gaaagggtccgtcagcatgac)-3”(配列番号4)
Nuclease-free Water(not DEPC-treated)(Ambion社製、Lot.0803015)
UGT1A1遺伝子 野生型配列挿入プラスミド(1×106コピー/μL)
UGT1A1遺伝子 変異型配列挿入プラスミド(1×106コピー/μL)
5μLの10×AccuPrime PCR Buffer I、1μLのForward primer、1μLのReverse priemrに総量が49μLとなるようNuclease-free Waterで調整した溶液に、1μLのUGT1A1遺伝子配列挿入プラスミドを添加し反応溶液とした。
C1000(バイオ・ラッド ラボラトリーズ社製)を用いて、PCR反応を行った。温度サイクルは以下に示す通りである。
94℃、30秒でテンプレートを熱変性させ、94℃を15秒、62℃を15秒、68℃を30秒の増幅サイクルを40サイクル行い、最後に68℃、5分で保温した。サンプルは使用するまで4℃で保存した。
準備したアニオン交換カラムを用いて、以下の条件でAS-PCR増幅産物を分離検出した。
システム:LC-20Aシリーズ(島津製作所社製)
溶離液:溶離液A 25mmol/Lトリス塩酸緩衝液(pH7.5)
溶離液B 25mmol/Lトリス塩酸緩衝液(pH7.5)+1mol/Lグアニジン塩酸塩
分析時間:アニオン交換カラム1を用いたときの分析時間は10分
アニオン交換カラム2を用いたときの分析時間は20分
溶出法:以下に示すグラジエント条件により、溶離液Bの混合比率を直線的に増加させた。
アニオン交換カラム1を用いたときの条件
0分(溶離液B60%)→10分(溶離液B80%)
アニオン交換カラム2を用いたときの条件
0分(溶離液B80%)→20分(溶離液B100%)
検体:UGT1A1*6領域の野生型271bp
UGT1A1*6領域の変異型274bp
流速:0.5mL/min(アニオン交換カラム1を用いたとき)
1.0mL/min(アニオン交換カラム2を用いたとき)
検出波長:260nm
試料注入量:10μL
比較例1では、UGT1A1*6領域の野生型76bpと変異型96bpとの分離検出を試みた。
AccuPrime Taq DNA Polymerase High Fidelity(Invitorgen社製、Lot.760816)
10× AccuPrime PCR Buffer I
AccuPrime Taq DNA Polymerase High Fidelity(5U/μL)
UGT1A1*6 primer(Operon Biotechnologies社製)
Forward(野生型)(10pmol/μL):5’-(cgcctcgttgtacatcagagcgg)-3’(配列番号1)
Forward(変異型)(10pmol/μL):5’-(atagttgtcctagcacctgacgcctcgttgtacatcagagcga)-3”(配列番号5)
Reverse(10pmol/μL):5’-(cacatcctccctttggaatggca)-3”(配列番号3)
Nuclease-free Water(not DEPC-treated)(Ambion社製、Lot.0803015)
UGT1A1遺伝子 野生型配列挿入プラスミド(1×106コピー/μL)
UGT1A1遺伝子 変異型配列挿入プラスミド(1×106コピー/μL)
5μLの10×AccuPrime PCR Buffer I、1μLのForward primer、1μLのReverse priemrに総量が49μLとなるようNuclease-free Waterで調整した溶液に、1μLのUGT1A1遺伝子配列挿入プラスミドを添加し反応溶液とした。
C1000(バイオ・ラッド ラボラトリーズ社製)を用いて、PCR反応を行った。温度サイクルは以下に示す通りである。
94℃、30秒でテンプレートを熱変性させ、94℃を15秒、62℃を15秒、68℃を30秒の増幅サイクルを40サイクル行い、最後に68℃、5分で保温した。サンプルは使用するまで4℃で保存した。
参考例2では、UGT1A1*6領域の野生型76bpと変異型79bpとの分離検出を行った。
Claims (4)
- AS-PCR法によって増幅された野生型と変異型の産物を、イオン交換クロマトグラフィーを用いて分析することを特徴とする一塩基多型の検出方法。
- AS-PCR法によって増幅された産物の大きさが200bp以下であり、かつ、野生型と変異型の鎖長差が10bp以下であることを特徴とする、請求項1記載の一塩基多型の検出方法。
- グアニジン塩は、グアニジン塩酸塩又はグアニジン硫酸塩であることを特徴とする、請求項3記載の一塩基多型の検出方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012552752A JP6061381B2 (ja) | 2011-01-12 | 2012-01-12 | 一塩基多型の検出方法 |
CN201280005010.3A CN103348242B (zh) | 2011-01-12 | 2012-01-12 | 单核苷酸多态性的检测方法 |
KR1020137020841A KR102047650B1 (ko) | 2011-01-12 | 2012-01-12 | 단일염기다형의 검출 방법 |
EP12734188.1A EP2664917B1 (en) | 2011-01-12 | 2012-01-12 | Method for detecting single nucleotide polymorphisms |
US13/979,256 US20140147842A1 (en) | 2011-01-12 | 2012-01-12 | Method for detecting single nucleotide polymorphisms |
US14/669,735 US9447460B2 (en) | 2011-01-12 | 2015-03-26 | Method for detecting single nucleotide polymorphisms |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011004216 | 2011-01-12 | ||
JP2011-004216 | 2011-01-12 | ||
JP2011-080369 | 2011-03-31 | ||
JP2011080369 | 2011-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/979,256 A-371-Of-International US20140147842A1 (en) | 2011-01-12 | 2012-01-12 | Method for detecting single nucleotide polymorphisms |
US14/669,735 Continuation US9447460B2 (en) | 2011-01-12 | 2015-03-26 | Method for detecting single nucleotide polymorphisms |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012096329A1 true WO2012096329A1 (ja) | 2012-07-19 |
Family
ID=46507221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/050430 WO2012096329A1 (ja) | 2011-01-12 | 2012-01-12 | 一塩基多型の検出方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20140147842A1 (ja) |
EP (1) | EP2664917B1 (ja) |
JP (1) | JP6061381B2 (ja) |
KR (1) | KR102047650B1 (ja) |
CN (1) | CN103348242B (ja) |
WO (1) | WO2012096329A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2012133834A1 (ja) * | 2011-03-31 | 2014-07-28 | 積水メディカル株式会社 | 一塩基多型検出用の試料核酸、一塩基多型検出試料調製用のpcrプライマー及びイオン交換クロマトグラフィー分析に用いる一塩基多型検出用試料の調製方法 |
WO2015129916A1 (ja) * | 2014-02-28 | 2015-09-03 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後判定方法 |
WO2017170101A1 (ja) * | 2016-03-31 | 2017-10-05 | 積水メディカル株式会社 | イオン交換クロマトグラフィーを用いた一塩基置換検出方法 |
WO2019022132A1 (ja) * | 2017-07-26 | 2019-01-31 | 積水メディカル株式会社 | 変異遺伝子検出方法 |
WO2019064483A1 (ja) * | 2017-09-29 | 2019-04-04 | 積水メディカル株式会社 | イオン交換クロマトグラフィーを用いた一塩基置換検出方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6570795B2 (ja) * | 2017-08-25 | 2019-09-04 | 積水メディカル株式会社 | メチル化dna分離及び/又は検出用クロマトグラフィー用充填剤 |
CN114577936B (zh) * | 2022-03-03 | 2024-06-04 | 中科谱研(北京)科技有限公司 | 一种胶囊中β-烟酰胺单核苷酸的分离检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001330969A (ja) | 2000-05-23 | 2001-11-30 | Sekisui Chem Co Ltd | フォトレジスト除去装置 |
JP2009524412A (ja) * | 2005-12-30 | 2009-07-02 | アンスティテュ・パストゥール | 核酸の混合物におけるpcrによる突然変異核酸の示差的増幅 |
JP2010504738A (ja) * | 2006-09-26 | 2010-02-18 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | 陰イオン交換を用いる核酸精製方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6098988A (ja) | 1983-11-01 | 1985-06-01 | Chemo Sero Therapeut Res Inst | Lpf−haの精製法 |
CA2063855C (en) | 1991-04-03 | 1997-08-26 | Will Bloch | Precision and accuracy of anion-exchange separation of nucleic acids |
US5438128A (en) | 1992-02-07 | 1995-08-01 | Millipore Corporation | Method for rapid purifiction of nucleic acids using layered ion-exchange membranes |
EP1146049B1 (de) | 1994-02-11 | 2005-08-17 | Qiagen GmbH | Verfahren zur Trennung von Doppelstrang/Einzelstrangnukleinsäurestrukturen |
SE9600590D0 (sv) | 1996-02-19 | 1996-02-19 | Pharmacia Biotech Ab | Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris |
US6265168B1 (en) * | 1998-10-06 | 2001-07-24 | Transgenomic, Inc. | Apparatus and method for separating and purifying polynucleotides |
EP1226275B1 (en) * | 1999-10-12 | 2008-09-10 | TRANSGENOMIC, Inc. | Detection of nucleic acid heteroduplex molecules by anion-exchange chromatography |
WO2002018656A2 (en) | 2000-08-30 | 2002-03-07 | Avi Biopharma, Inc. | Method for analysis of oligonucleotide analogs |
CN1451762A (zh) | 2002-04-12 | 2003-10-29 | 刘湘军 | 通过pcr产物不同长度测定snp |
JP2004180637A (ja) * | 2002-12-06 | 2004-07-02 | Fuji Photo Film Co Ltd | 核酸の分離精製装置 |
JP4228041B2 (ja) | 2003-07-08 | 2009-02-25 | 東洋紡績株式会社 | 塩基多型の検出方法 |
JP4491276B2 (ja) | 2004-05-17 | 2010-06-30 | 日本製粉株式会社 | 標的dna配列において一塩基変異多型の存在を検出する方法及びキット |
JP2006075126A (ja) | 2004-09-13 | 2006-03-23 | National Institute Of Advanced Industrial & Technology | 一塩基変異を検出する方法および検出用プローブ |
US8058410B2 (en) | 2005-04-26 | 2011-11-15 | Sandoz Ag | Affinity ligands |
CN1880480A (zh) | 2006-04-12 | 2006-12-20 | 重庆医科大学 | 检测等位基因特异引物-pcr方法及其在检测克老素基因多态性中的应用 |
GB2443505B (en) * | 2006-09-26 | 2008-12-31 | Ge Healthcare Bio Sciences | Nucleic acid purification method |
CN101323852B (zh) | 2007-06-11 | 2013-01-23 | 北京东胜创新生物科技有限公司 | 一种在自动化核酸提取工作站上进行基因组提取的试剂盒及方法 |
US20090053719A1 (en) * | 2007-08-03 | 2009-02-26 | The Chinese University Of Hong Kong | Analysis of nucleic acids by digital pcr |
CN101899437B (zh) * | 2010-04-15 | 2012-04-25 | 浙江大学 | 用于甜瓜枯萎病抗性鉴定的功能性分子标记及其用途 |
CN101899511B (zh) | 2010-07-09 | 2012-08-08 | 华中农业大学 | 应用as-pcr检测牛白细胞粘附缺陷的方法 |
CN104946626A (zh) | 2011-01-12 | 2015-09-30 | 积水医疗株式会社 | 离子交换色谱法用洗脱液以及核酸链的分析方法 |
CN103443274A (zh) | 2011-03-31 | 2013-12-11 | 积水医疗株式会社 | 单核苷酸多态性检测用的试样核酸、单核苷酸多态性检测试样制备用的pcr引物以及用于离子交换色谱法分析的单核苷酸多态性检测用试样的制备方法 |
-
2012
- 2012-01-12 US US13/979,256 patent/US20140147842A1/en not_active Abandoned
- 2012-01-12 CN CN201280005010.3A patent/CN103348242B/zh active Active
- 2012-01-12 EP EP12734188.1A patent/EP2664917B1/en active Active
- 2012-01-12 WO PCT/JP2012/050430 patent/WO2012096329A1/ja active Application Filing
- 2012-01-12 KR KR1020137020841A patent/KR102047650B1/ko active IP Right Grant
- 2012-01-12 JP JP2012552752A patent/JP6061381B2/ja active Active
-
2015
- 2015-03-26 US US14/669,735 patent/US9447460B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001330969A (ja) | 2000-05-23 | 2001-11-30 | Sekisui Chem Co Ltd | フォトレジスト除去装置 |
JP2009524412A (ja) * | 2005-12-30 | 2009-07-02 | アンスティテュ・パストゥール | 核酸の混合物におけるpcrによる突然変異核酸の示差的増幅 |
JP2010504738A (ja) * | 2006-09-26 | 2010-02-18 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | 陰イオン交換を用いる核酸精製方法 |
Non-Patent Citations (4)
Title |
---|
GAUDET M. ET AL.: "Allele-specific PCR in SNP genotyping", METHODS MOL BIOL., vol. 578, 2009, pages 415 - 424, XP009177497 * |
NATURE, vol. 324, 1986, pages 163 - 166 |
See also references of EP2664917A4 |
TSUCHIHASHI Z. ET AL.: "Progress in high throughput SNP genotyping methods", PHARMACOGENOMICS J., vol. 2, no. 2, 2002, pages 103 - 110, XP008010361 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2012133834A1 (ja) * | 2011-03-31 | 2014-07-28 | 積水メディカル株式会社 | 一塩基多型検出用の試料核酸、一塩基多型検出試料調製用のpcrプライマー及びイオン交換クロマトグラフィー分析に用いる一塩基多型検出用試料の調製方法 |
WO2015129916A1 (ja) * | 2014-02-28 | 2015-09-03 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後判定方法 |
CN106062215A (zh) * | 2014-02-28 | 2016-10-26 | 国立研究开发法人国立癌研究中心 | 肾细胞癌的预后判定方法 |
US10190172B2 (en) | 2014-02-28 | 2019-01-29 | National Cancer Center | Method for determining prognosis of renal cell carcinoma |
CN111057752A (zh) * | 2014-02-28 | 2020-04-24 | 国立研究开发法人国立癌研究中心 | 离子交换色谱的应用和pcr引物的应用 |
CN106062215B (zh) * | 2014-02-28 | 2020-09-22 | 国立研究开发法人国立癌研究中心 | 肾细胞癌的预后判定方法 |
WO2017170101A1 (ja) * | 2016-03-31 | 2017-10-05 | 積水メディカル株式会社 | イオン交換クロマトグラフィーを用いた一塩基置換検出方法 |
WO2019022132A1 (ja) * | 2017-07-26 | 2019-01-31 | 積水メディカル株式会社 | 変異遺伝子検出方法 |
WO2019064483A1 (ja) * | 2017-09-29 | 2019-04-04 | 積水メディカル株式会社 | イオン交換クロマトグラフィーを用いた一塩基置換検出方法 |
CN109863245A (zh) * | 2017-09-29 | 2019-06-07 | 积水医疗株式会社 | 使用离子交换层析的单碱基置换检测方法 |
US10626452B2 (en) | 2017-09-29 | 2020-04-21 | Sekisui Medical Co., Ltd. | Method for detecting single base substitution using ion-exchange chromatography |
Also Published As
Publication number | Publication date |
---|---|
KR20140041421A (ko) | 2014-04-04 |
US9447460B2 (en) | 2016-09-20 |
EP2664917B1 (en) | 2017-09-06 |
US20150197795A1 (en) | 2015-07-16 |
JPWO2012096329A1 (ja) | 2014-06-09 |
EP2664917A1 (en) | 2013-11-20 |
KR102047650B1 (ko) | 2019-11-22 |
CN103348242B (zh) | 2016-08-17 |
CN103348242A (zh) | 2013-10-09 |
US20140147842A1 (en) | 2014-05-29 |
EP2664917A4 (en) | 2015-01-07 |
JP6061381B2 (ja) | 2017-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6061381B2 (ja) | 一塩基多型の検出方法 | |
JP5930443B2 (ja) | 核酸鎖分離検出用イオン交換クロマトグラフィー用充填剤及び核酸鎖分離検出用イオン交換クロマトグラフィー用カラム | |
JP6222639B2 (ja) | メチル化dnaの検出方法 | |
WO2015129916A1 (ja) | 腎細胞癌の予後判定方法 | |
WO2012133834A1 (ja) | 一塩基多型検出用の試料核酸、一塩基多型検出試料調製用のpcrプライマー及びイオン交換クロマトグラフィー分析に用いる一塩基多型検出用試料の調製方法 | |
JP6090985B2 (ja) | 核酸鎖の分離方法 | |
WO2019039532A1 (ja) | 肝細胞癌のリスク評価方法 | |
JP6977933B2 (ja) | 腎細胞癌の予後判定方法 | |
WO2016024634A1 (ja) | インプリンティング疾患の診断に有効な染色体機能異常の判定方法 | |
JP5812464B2 (ja) | 標的核酸の分離検出方法、標的核酸分離検出用イオン交換クロマトグラフィー用充填剤、及び標的核酸分離検出用イオン交換クロマトグラフィー用カラム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12734188 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012552752 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2012734188 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012734188 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137020841 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13979256 Country of ref document: US |